Literature DB >> 7616369

Bayesian estimation of p-aminohippurate clearance by a limited sampling strategy.

J M Kinowski1, M Rodier, F Bressolle, D Fabre, V Augey, J L Richard, M Galtier, R Gomen.   

Abstract

This study describes a methodology to calculated p-aminohippurate (PAH) clearance (CL) and volume of distribution (V) with both the population parameters and one or two samples taken during the disposition and the elimination phase after a single intravenous infusion. The computer program P-PHARM was used, and a log-normal distribution and a heteroscedastic residual error distribution were assumed. Ninety-six patients with and without renal insufficiency were available for analysis, and a two-compartment model was used for data modeling. Population parameters were evaluated for 70 patients (mean number of observed concentration per individual, 6) by a three-step approach. In step 1, the computer program was used to estimate the average pharmacokinetic parameters without taking into account the demographic and/or biological factors. In step 2, the relationship between the posterior individual estimates and the covariables was investigated with multiple linear stepwise algorithm. In step 3, the population parameters were re-estimated considering the relationship with the covariables. From the regression performed in step 2, the following covariables were included: serum creatinine, body surface area, and body weight. The population averages of CL and V were 30.7 +/- 2.36 L/h and 10.6 +/- 1.29 L, respectively. To evaluate the predictive performance of the population parameters, the remaining 26 patients were used. The population parameters combined with one or two individual PAH plasma concentrations led to a bayesian estimation of individual CL and V. This estimation was compared with the classical procedure of parameter estimation (individual fitting from multiple blood samples).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7616369     DOI: 10.1002/jps.2600840309

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  6 in total

1.  A comparison of a Bayesian population method with two methods as implemented in commercially available software.

Authors:  J E Bennett; J C Wakefield
Journal:  J Pharmacokinet Biopharm       Date:  1996-08

2.  Population pharmacokinetics of amphotericin B in children with malignant diseases.

Authors:  C E Nath; A J McLachlan; P J Shaw; R Gunning; J W Earl
Journal:  Br J Clin Pharmacol       Date:  2001-12       Impact factor: 4.335

3.  Simultaneous administration of a cocktail of markers to measure renal drug elimination pathways: absence of a pharmacokinetic interaction between fluconazole and sinistrin, p-aminohippuric acid and pindolol.

Authors:  A S Gross; A J McLachlan; I Minns; J B Beal; S E Tett
Journal:  Br J Clin Pharmacol       Date:  2001-06       Impact factor: 4.335

Review 4.  What is the best size descriptor to use for pharmacokinetic studies in the obese?

Authors:  Bruce Green; Stephen B Duffull
Journal:  Br J Clin Pharmacol       Date:  2004-08       Impact factor: 4.335

Review 5.  Principles and clinical application of assessing alterations in renal elimination pathways.

Authors:  Susan E Tett; Carl M J Kirkpatrick; Annette S Gross; Andrew J McLachlan
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

6.  Conventional Pig as Animal Model for Human Renal Drug Excretion Processes: Unravelling the Porcine Renal Function by Use of a Cocktail of Exogenous Markers.

Authors:  Laura Dhondt; Siska Croubels; Peter De Paepe; Steven C Wallis; Saurabh Pandey; Jason A Roberts; Jeffrey Lipman; Pieter De Cock; Mathias Devreese
Journal:  Front Pharmacol       Date:  2020-06-12       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.